Related references
Note: Only part of the references are listed.Control of Pancreatic β Cell Regeneration by Glucose Metabolism
Shay Porat et al.
CELL METABOLISM (2011)
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
Gary E. Meininger et al.
DIABETES CARE (2011)
Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs
Jun-ichi Eiki et al.
MOLECULAR PHARMACOLOGY (2011)
Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function
Akinobu Nakamura et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
Riccardo C. Bonadonna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Large Islets, Beta-Cell Proliferation, and a Glucokinase Mutation.
Sameer Kassem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
David M. Kendall et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy
Tomoharu Iino et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells
P. Wei et al.
DIABETOLOGIA (2009)
Impact of Small-Molecule Glucokinase Activator on Glucose Metabolism and β-Cell Mass
Akinobu Nakamura et al.
ENDOCRINOLOGY (2009)
Assessing the potential of glucokinase activators in diabetes therapy
Franz M. Matschinsky
NATURE REVIEWS DRUG DISCOVERY (2009)
Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice
T. Gorman et al.
DIABETES OBESITY & METABOLISM (2008)
Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator
Daniel Johnson et al.
DIABETES (2007)
Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions
M. C. T. Fyfe et al.
DIABETOLOGIA (2007)
Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance
Yasuo Terauchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism
Mayumi Futamura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats
G. J. Coope et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet β-cells
Melissa K. Lingohr et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A novel glucokinase activator modulates pancreatic islet and hepatocyte function
AM Efanov et al.
ENDOCRINOLOGY (2005)
ATP-sensitive potassium channelopathies: focus on insulin secretion
FM Ashcroft
JOURNAL OF CLINICAL INVESTIGATION (2005)
Pdx1 expression in Irs2-deficient mouse β-cells is regulated in a strain-dependent manner
R Suzuki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Allosteric activators of glucokinase: Potential role in diabetes therapy
J Grimsby et al.
SCIENCE (2003)
CAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2
US Jhala et al.
GENES & DEVELOPMENT (2003)
Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes
T Nishikawa et al.
DIABETES CARE (2003)
beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
AE Butler et al.
DIABETES (2003)
Profound defects in pancreatic β-cell function in mice with combined heterozygous mutations in Pdx-1, Hnf-1α, and Hnf-3β
DQ Shih et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory β-cell hyperplasia
N Kubota et al.
DIABETES (2000)
Share Paper
